

Reference List

CBD and Cannabis Use at the End of Life: Evolution and Evidence

by Janice Newell Bissex, MS, RD, FAND

June 3, 2020

References:

1. Ahmed AIA, van den Elsen GAH, Colbers A, et al. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. *Psychopharmacology (Berl)*. 2015;232(14):2587-2595.
2. Ancient history timeline. Holistic Cannabis Academy website. <http://holisticcannabisacademy.com>. Accessed February 7, 2020.
3. Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. *Ther Adv Psychopharmacol*. 2012;2(6):241-254.
4. Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. *Curr Psychiatry Rep*. 2017;19(4):23.
5. Beale C, Broyd SJ, Chye Y, et al. Prolonged cannabidiol treatment effects on hippocampal subfield volumes in current cannabis users. *Cannabis Cannabinoid Res*. 2018;3(1):94-107.
6. Blake DK. Marijuana statistics 2019, usage, trends and data. American Marijuana website. <https://americanmarijuana.org/marijuana-statistics/>. Updated January 30, 2020. Accessed February 29, 2020.
7. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. *JAMA*. 2017;318(17):1708-1709.
8. Bonn-Miller MO, ElSohly MA, Loflin MJE, Chandra S, Vandrey R. Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches. *Int Rev Psychiatry*. 2018;30(3):277-284.
9. Cannabidiol (CBD) — what we know and what we don't. Harvard Health Publishing website. <https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476>. Updated April 15, 2020.
10. Cannabinoids as antioxidants and neuroprotectants. PubChem website. <https://pubchem.ncbi.nlm.nih.gov/patent/US6630507>
11. Devitt-Lee A. CBD-drug interactions: role of cytochrome P450. Project CBD website. <https://www.projectcbd.org/medicine/cbd-drug-interactions/p450>. Published September 8, 2015. Accessed March 24, 2020.
12. Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. *Lancet Psychiatry*. 2019;6(5):P427-P436.
13. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. *Diabetologia*. 2008;51(8):1356-1367.
14. DiPatrizio NV. Endocannabinoids in the gut. *Cannabis Cannabinoid Res*. 2016;1(1):67-77.
15. Dosage. Holistic Cannabis Academy website. <http://holisticcannabisacademy.com>. Accessed February 7, 2020.
16. Drug scheduling. US Drug Enforcement Administration website. <https://www.dea.gov/drug-scheduling>. Accessed February 7, 2020.
17. Esposito G, De Filippis D, Cirillo C, et al. Cannabidiol in inflammatory bowel diseases: a brief overview. *Phytother Res*. 2013;27(5):633-636.

18. Evanoff AB, Quan T, Dufault C, Awad M, Beirut LJ. Physicians-in-training are not prepared to prescribe medical marijuana. *Drug Alcohol Depend.* 2017;180:151-155.
19. Fairbairn CE, Briley DA, Kang D, Fraley CR, Hankin BL, Ariss T. A meta-analysis of longitudinal associations between substance use and interpersonal attachment security. *Psychol Bull.* 2018;144(5):532-555.
20. Fernández-Ruiz J, Moro MA, Martínez-Orgado J. Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. *Neurotherapeutics.* 2015;12(4):793-806.
21. Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. *Biol Psychiatry.* 2016;79(7):549-556.
22. Garey J. Marijuana and psychosis. Child Mind Institute website. <https://childmind.org/article/marijuana-and-psychosis/>
23. Gong H Jr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids. *Clin Pharmacol Ther.* 1984;35(1):26-32.
24. Historical timeline. ProCon.org website. <https://medicalmarijuana.procon.org/historical-timeline/>. Accessed February 7, 2020.
25. Idris AI, Sophocleous A, Landao-Bassonga E, et al. Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. *Cell Metab.* 2009;10(2):139-147.
26. Institute of Medicine. Marijuana and medicine: assessing the science base. <https://www.ncbi.nlm.nih.gov/books/NBK230716/?report=reader>. Published 1999. Accessed February 7, 2020.
27. Jacobs M. The difference between cannabinoids and terpenes. Analytical Cannabis website. <https://www.analyticalcannabis.com/articles/the-difference-between-cannabinoids-and-terpenes-311502>. Published February 21, 2019. Accessed May 12, 2020.
28. Jadoon KA, Ratcliffe SH, Barrett DA, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. *Diabetes Care.* 2016;39(10):1777-1786.
29. Karhson DS, Krasinska KM, Dallaire JA, et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. *Mol Autism.* 2018;9:18.
30. Kogan NM, Melamed E, Wasserman E, et al. Cannabidiol, a major non-psychoactive cannabis constituent enhances fracture healing and stimulates lysyl hydroxylase activity in osteoblasts. *J Bone Miner Res.* 2015;30(10):1905-1913.
31. Kossen J. How does cannabis interact with other drugs? <https://www.leafly.com/news/health/cannabis-cannabinoids-drug-interactions>. Published March 23, 2017.
32. Lee JLC, Bertoglio LJ, Guimarães FS, Stevenson CW. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. *Br J Pharmacol.* 2017;174(19):3242-3256.
33. Manzanares J, Julian MD, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. *Curr Neuropharmacol.* 2006;4(3):239-257.
34. Medicinal use of marijuana. *N Engl J Med.* 2013;368:866-868.
35. National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. <https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state>. Published 2017.

36. Oláh A, Tóth BI, Borbíró I, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. *J Clin Invest*. 2014;124(9):3713-3724.
37. Patel S, Shua-Hain JR, Pass M. Safety and efficacy of dronabinol in the treatment of agitation in patients with Alzheimer's disease with ANOREXIA: A retrospective chart review. Paper presented at: International Psychogeriatric Association Eleventh International Congress; August 2003; Chicago, IL.
38. Penner EA, Buettner H, Mittleman MA. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. *Am J Med*. 2013;126(7):583-589.
39. Pretzsch CM, Freyberg J, Voinescu B, et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. *Neuropsychopharmacology*. 2019;44(8):1398-1405.
40. Reid MC, Eccleston C, Pillemer K. Management of chronic pain in older adults. *BMJ*. 2015;350:h532
41. Rettew D. Does marijuana cause psychosis? *Psychology Today* website. <https://www.psychologytoday.com/us/blog/abcs-child-psychiatry/201601/does-marijuana-cause-psychosis>. Published January 6, 2016. Accessed April 7, 2020
42. Ross JM, Ellingson JM, Rhee SH, et. al. Investigating the causal effect of cannabis use on cognitive function with a quasi-experimental co-twin design. *Drug Alcohol Depend*. 2020;206:107712.
43. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol*. 2011;163(7):1344-1364.
44. Sallaberry CA, Astern L. The endocannabinoid system, our universal regulator. *J Young Investig*. 2018;34(6):48-55.
45. Turcotte C, Blanchet MR, Lavoilette M, Flamand N. The CB2 receptor and its role as a regulator of inflammation. *Cell Mol Life Sci*. 2016;73:4449-4470.
46. 2018 Farm Bill. United States Senate Committee on Agriculture, Nutrition, & Forestry website. <https://www.agriculture.senate.gov/2018-farm-bill>. Accessed February 7, 2020.
47. Walter J. What science knows about marijuana's health benefits. Discover website. <https://www.discovermagazine.com/mind/what-science-knows-about-marijuanas-health-benefits>. Published February 7, 2020. Accessed February 29, 2020.
48. Weed: a CNN report by Dr. Sanjay Gupta. CannaTech website. <https://www.canna-tech.co/uncategorized/weed-a-cnn-special-report-by-dr-sanjay-gupta/>. Published June 16, 2016. Accessed February 7, 2020.
49. Weed & the American family. Marist Poll website. <http://maristpoll.marist.edu/yahoo-news-marist-poll/#sthash.xJBqyZYP.Gpzcd2Hv.dpbs>. Accessed February 29, 2020.
50. Weiss L, Zeira M, Reich S, et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. *Autoimmunity*. 2006;39(2):143-151.
51. What is marijuana? National Institute on Drug Abuse website. <https://www.drugabuse.gov/publications/drugfacts/marijuana>. Updated December 2019. Accessed April 7, 2020.
52. Wiese B, Wilson-Poe AR. Emerging evidence for cannabis' role in opioid use disorder. *Cannabis Cannabinoid Res*. 2018;3(1):179-189.
53. Wium-Anderson MK, Ørsted DD, Nielsen SF, Nordestgaard BG. Elevated C-reactive protein levels, psychological distress, and depression in 73,131 individuals. *JAMA Psychiatry*. 2013;70(2):176-184.

54. World Health Organization. Cannabidiol (CBD): critical review report.
<https://www.who.int/medicines/access/controlled-substances/CannabidiolCriticalReview.pdf>.
Published 2018. Accessed February 27, 2020.